Form 4: Supernus Pharmaceuticals SVP & CFO Timothy Dec Reports Acquisition of Performance Share Units

Sentiment:

SEC Form 4 Filing


Timothy Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition of performance share units.

Summary

  • On March 4, 2025, Timothy C. Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, filed a Form 4.
  • The report details the acquisition of performance share units.
  • On February 28, 2025, Dec acquired 2,000 Performance Share Units related to common stock, stemming from an award on February 23, 2023, with objectives set on June 12, 2023.
  • Additionally, Dec acquired 1,800 Performance Share Units related to common stock, stemming from an award on February 22, 2024, with objectives set on June 24, 2024.
  • Following the reported transactions, Dec directly owns 14,091 shares of common stock and 3,800 Performance Share Units.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently convey positive or negative sentiment.

Positives

  • The reporting person's holdings in the company have increased.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the actions of company executives.

Stakeholder Impact

  • The filing provides transparency to shareholders regarding the actions of company executives.

Key Dates

DateDescription
02/23/2023Reporting Person was awarded Performance Share Units
06/12/2023Objectives were established for Performance Share Units awarded on February 23, 2023
02/22/2024Reporting Person was awarded Performance Share Units
06/24/2024Objectives were established for Performance Share Units awarded on February 22, 2024
02/28/2025Transaction Date: Acquisition of Performance Share Units
03/04/2025Date of Form 4 Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.